1-3 of 3
Nancy Guzzo-Pernell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Significant Reduction of BCR-ABL Transcripts after Switching to Imatinib Therapy in Patients with CML and Complete or Near-Complete Cytogenetic Responses to Interferon-Alpha (IFN).

Susan Branford, Timothy Hughes, Steven Stylian, Anthony P. Schwarer, Chris Arthur, Robin Filshie, Susan Moreton, Robyn Rodwell, Nancy Guzzo-Pernell, Deb Taylor, Jenny Larson, Rachel Koelmayer, Alvin Milner, Kevin Lynch, Kerry McDonald Taylor
Journal: Blood
Blood (2006) 108 (11): 2142.
https://doi.org/10.1182/blood.V108.11.2142.2142
Published: 2006
Journal Articles

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Timothy P. Hughes, Susan Branford, John Reynolds, Rachel Koelmeyer, John Seymour, Kerry Taylor, Nancy Guzzo-Pernell, Robin Filshie, Chris Arthur, Anthony Schwarer, Mark Hertzberg, Michael Copeman, Kevin Lynch, Andrew Grigg
Journal: Blood
Blood (2005) 106 (11): 164.
https://doi.org/10.1182/blood.V106.11.164.164
Published: 2005
Journal Articles

Imatinib’s Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML.

John Francis Seymour, MBBS FRACP, Andrew Grigg, MBBS FRACP, John Reynolds, Jane Matthews, Anthony P. Schwarer, MBBS FRACP, Richard Herrmann, MBBS FRACP, Kerry McDonald Taylor, MBBS FRACP, Mark S. Hertzberg, MBBS FRACP, Anthony Mills, MBBS FRACP, Nancy Guzzo-Pernell, Michael Copeman, MBBS FRACP, Kevin Lynch, MBBS, Timothy Hughes, MBBS FRACP
Journal: Blood
Blood (2004) 104 (11): 1020.
https://doi.org/10.1182/blood.V104.11.1020.1020
Published: 2004